SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 53 filers reported holding SPERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $554 | -16.6% | 458 | 0.0% | 0.00% | – |
| Q2 2023 | $664 | -99.7% | 458 | -98.1% | 0.00% | – |
| Q1 2022 | $215,000 | -30.2% | 24,740 | +28.4% | 0.00% | – |
| Q4 2021 | $308,000 | -14.7% | 19,261 | -1.7% | 0.00% | – |
| Q3 2021 | $361,000 | +39.4% | 19,590 | +5.5% | 0.00% | – |
| Q2 2021 | $259,000 | -4.4% | 18,565 | +0.7% | 0.00% | – |
| Q1 2021 | $271,000 | -27.3% | 18,439 | -4.0% | 0.00% | -100.0% |
| Q4 2020 | $373,000 | +128.8% | 19,216 | +31.2% | 0.00% | – |
| Q3 2020 | $163,000 | -32.9% | 14,648 | -18.3% | 0.00% | – |
| Q2 2020 | $243,000 | +82.7% | 17,929 | +9.2% | 0.00% | – |
| Q1 2020 | $133,000 | -10.1% | 16,417 | +6.7% | 0.00% | – |
| Q4 2019 | $148,000 | -6.9% | 15,387 | +2.3% | 0.00% | – |
| Q3 2019 | $159,000 | +1.9% | 15,042 | +10.9% | 0.00% | – |
| Q2 2019 | $156,000 | +11.4% | 13,561 | +24.5% | 0.00% | – |
| Q1 2019 | $140,000 | +125.8% | 10,893 | +8.8% | 0.00% | – |
| Q4 2018 | $62,000 | – | 10,010 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |